AnaptysBio FY27 Q1 income from continuing operations drops 93% to $3.88 million
ANAB•AnaptysBio reported $3.88 million in net income for its fiscal first quarter, down 74% year over year, while collaboration revenue fell 60% to $30.27 million. A judgment in litigation involving GSK and Tesaro is expected in calendar Q4 2026 or Q1 2027.
1. Quarterly results
AnaptysBio's net income fell 74% year over year to $3.88 million for the fiscal first quarter ended September 30, 2026. Collaboration revenue dropped 60% to $30.27 million, primarily because the year-earlier quarter included $50 million in milestone revenue.
2. Litigation and FDA date
A judgment in litigation against GSK and Tesaro is expected in calendar Q4 2026 or Q1 2027; AnaptysBio seeks reversion of Jemperli rights. Quimilza's FDA target action date for generalized pustular psoriasis is December 12, 2026.
